培美曲赛联合香菇多糖治疗肺腺癌并恶性心包积液疗效观察

Effect observation of pemetrexed combined lentiana in treactment of lung carcioma with malignant pericardial

目的评价培美曲塞联合香菇多糖对初治肺腺癌并恶性心包积液的临床疗效和不良反应。方法 30例病理确诊初治肺腺癌并恶性心包积液患者,随机分入培美曲赛联合香菇多糖局部灌注组及顺铂局部灌注组;两周期后评价疗效。结果 30例可评价,两组总RR分别为:66.6%和86.6%两组比较无统计学差异;中位无疾病进展生存期分别为:(8.076±0.456)个月和(5.122±0.335)个月,差异具有统计学意义。结论培美曲塞联合香菇多糖一线治疗的肺腺癌并恶性心包积液患者,具有较好的疗效和安全性。

Objective To observe the clinical and adverse effect of the effusion and toxicity of pemetrexed plus lentinan as the first-line treatment for lung cancer with malignant pericardial.Methods Totally 30 patients diagnosed early treating lung adenocarcinoma and malignant pericardial effusion were randomly assigned to pemetrexed combined local injection of lentinan group and local perfusion with cisplatin group;Tvaluated after two cycles.Results Totally 30 evaluable cases,the total RR groups were 66.6% and 86.6% no significant difference between the two groups;Median progression-free survival were（8.076±0.456） months and（5.122±0.335） months statistical significance.Conclusions Pemetrexed plus lentinan as first-line treatment for lung adenocarcinoma and pericardial effusion,and has good efficacy and safety.